JPRN-UMIN000008277已完成2 期
A Prospective Phase II Multicenter Study for Prophylaxis of Acute Exacerbations of Interstitial Lung Disease after Lung Cancer Resection - Sivelestat sodium Hydrate with low dose methylprednisolone for prevention of postoperative Interstitial Pneumonia (SHIP)
Yokohama Consortium of Thoracic Surgeons0 个研究点目标入组 70 人开始时间: 2012年6月29日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)History of cancer treatment within 5 years (except carcinoma in situ). History of radiation therapy (which include a lung in the treatment field) or chemotherapy. 2)Severe comorbidities (uncontrolled ischemic heart disease or myocardial infarction within three months. Uncontrolled diabetes, hypertension and infection) 3)Pregnant ladies, nursing ladies, the ladies with possibility of pregnancy. 4)Patients who takes steroid therapy 5)Treatment history of interstitial pneumonia with pirfenidone.
研究者
相似试验
终止
2 期
A Phase 2 Multi-Centre Study to Characterise the Pharmacodynamics of Vessel Dilator Peptide (VSDL) in Patients with Acute Decompensated Congestive Heart Failure to be assessed by effects on renal function.Acute Decompensated Congestive Heart FailureCardiovascular - Other cardiovascular diseasesACTRN12613001060730South Australian Health and Medical Research Institute65
尚未招募
不适用
Prophylactic administation of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-containing regimeNeoplasmsKCT0002985Chonnam National University Hospital Hwasun Hospital33
进行中（未招募）
不适用
A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney cancerEUCTR2006-004857-86-FRCaprion Pharmaceuticals Inc.40
已完成
2 期
Multicenter Phase II Clinical Study of the research on optimal assessments and treatment strategy of nilotinib in newly diagnosed chronic myelogenous leukemia patients in the chronic phase (CML-CP) based on early achievement of complete molecular response (CMR); N-roadChronic Myelogenous LeukemiaJPRN-UMIN000008565Cooperative study between Jikei University Kashiwa Hospital and Shimousa Hematology Study Group50
已完成
4 期
Postmarketing safety evaluation of recombinant anti-Rho (D) immunoglobuliCTRI/2021/11/038206Bharat Serums and Vaccines Ltd300